CDK4 and acute lymphoblastic leukemia: Additionally, the inhibitor palbociclib, which targets the CDK4/6-cyclin D complex pathway, demonstrates substantial therapeutic potential for B-ALL, with its efficacy validated in multiple preclinical and clinical studies [53,54].